Scinai Immunotherapeutics (FRA:2F5) ROCE % : 403.58% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Scinai Immunotherapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Scinai Immunotherapeutics's annualized ROCE % for the quarter that ended in Sep. 2024 was 403.58%.

Scinai Immunotherapeutics ROCE % Historical Data

The historical data trend for Scinai Immunotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics ROCE % Chart

Scinai Immunotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-109.46

-7.31

-79.03

-42.16

-47.17

Scinai Immunotherapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-48.36	-44.06	-50.14	-57.58	403.58

Scinai Immunotherapeutics ROCE % Calculation

Scinai Immunotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-8.9	/	( ( (25.551 - 2.207)	+	(16.022 - 1.632) )	/ 2 )
	=	-8.9	/	( (23.344	+	14.39)	/ 2 )
	=	-8.9	/	18.867
	=	-47.17 %

Scinai Immunotherapeutics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	44.468	/	( ( (13.797 - 1.553)	+	(11.047 - 1.254) )	/ 2 )
	=	44.468	/	( ( 12.244	+	9.793 )	/ 2 )
	=	44.468	/	11.0185
	=	403.58 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Scinai Immunotherapeutics (FRA:2F5) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Scinai Immunotherapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Scinai Immunotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (FRA:2F5) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SCNI:USA

Address

Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR

Website

https://www.biondvax.com

Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

Scinai Immunotherapeutics Headlines

No Headlines